FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387020131> ?p ?o ?g. }

• W4387020131 endingPage "1522" @default.
• W4387020131 startingPage "1522" @default.
• W4387020131 abstract "Qatar was also hit hard by the global pandemic of SARS-CoV-2, with the original virus, Alpha variant, Beta variant, Omicron BA.1 and BA.2 variants, Omicron BA.4 and BA.5 variants, and Delta variant, sequentially. The two-dose primary series of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against SARS-CoV-2 infection has been approved for use in 30 µg formulations among children and adolescents aged 12–17 years as of 16 May 2021. This study aimed at estimating the effectiveness of the 30 µg BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine against the pre-Omicron variants of SARS-CoV-2 infection in children and adolescents aged 12–17 years residing in Qatar. A test-negative matched case-control study was conducted. The subjects included any child or adolescent aged 12–17 years who had been tested for SARS-CoV-2 using RT-PCR tests performed on nasopharyngeal or oropharyngeal swabs, as part of contact tracing, between June and November 2021, and was eligible to receive the BNT162b2 vaccine as per the national guidelines. Data regarding 14,161 children/adolescents meeting inclusion–exclusion criteria were retrieved from the national Surveillance and Vaccine Electronic System (SAVES). Of the total, 3.1% (444) were positive for SARS-CoV-2. More than half (55.96%) were vaccinated with two doses of Pfizer-BioNTech-mRNA COVID-19 vaccine. Amongst those immunized with two doses, 1.2% tested positive for SARS-CoV-2, while 5.6% amongst the unvaccinated tested positive. The vaccine effectiveness was calculated to be 79%. Pfizer-BioNTech mRNA COVID-19 vaccine provides protection from COVID-19 infection for children/adolescents; hence, it is crucial to ensure they receive the recommended vaccines." @default.
• W4387020131 created "2023-09-26" @default.
• W4387020131 creator A5019587154 @default.
• W4387020131 creator A5020462763 @default.
• W4387020131 creator A5024982007 @default.
• W4387020131 creator A5030560916 @default.
• W4387020131 creator A5059802994 @default.
• W4387020131 creator A5062757491 @default.
• W4387020131 creator A5070119477 @default.
• W4387020131 creator A5072683663 @default.
• W4387020131 creator A5077282085 @default.
• W4387020131 creator A5092806576 @default.
• W4387020131 creator A5092806577 @default.
• W4387020131 creator A5092806579 @default.
• W4387020131 creator A5092806580 @default.
• W4387020131 date "2023-09-25" @default.
• W4387020131 modified "2023-09-26" @default.
• W4387020131 title "Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar" @default.
• W4387020131 cites W2010123683 @default.
• W4387020131 cites W2605758023 @default.
• W4387020131 cites W3010890049 @default.
• W4387020131 cites W3091793435 @default.
• W4387020131 cites W3097697379 @default.
• W4387020131 cites W3111590711 @default.
• W4387020131 cites W3122661585 @default.
• W4387020131 cites W3129580280 @default.
• W4387020131 cites W3134683097 @default.
• W4387020131 cites W3138604848 @default.
• W4387020131 cites W3151753940 @default.
• W4387020131 cites W3157162195 @default.
• W4387020131 cites W3158710728 @default.
• W4387020131 cites W3158925955 @default.
• W4387020131 cites W3160457188 @default.
• W4387020131 cites W3164094536 @default.
• W4387020131 cites W3164336383 @default.
• W4387020131 cites W3164720238 @default.
• W4387020131 cites W3168152565 @default.
• W4387020131 cites W3177903130 @default.
• W4387020131 cites W3200630639 @default.
• W4387020131 cites W3210921815 @default.
• W4387020131 cites W3212487860 @default.
• W4387020131 cites W4200191029 @default.
• W4387020131 cites W4200329071 @default.
• W4387020131 cites W4205483821 @default.
• W4387020131 cites W4211242522 @default.
• W4387020131 cites W4220678484 @default.
• W4387020131 cites W4220692166 @default.
• W4387020131 cites W4220758034 @default.
• W4387020131 cites W4225505755 @default.
• W4387020131 cites W4225612109 @default.
• W4387020131 cites W4226269906 @default.
• W4387020131 cites W4226443227 @default.
• W4387020131 cites W4229056531 @default.
• W4387020131 cites W4281827985 @default.
• W4387020131 cites W4282958946 @default.
• W4387020131 cites W4283717981 @default.
• W4387020131 cites W4283756122 @default.
• W4387020131 cites W4283812469 @default.
• W4387020131 cites W4308059494 @default.
• W4387020131 doi "https://doi.org/10.3390/vaccines11101522" @default.
• W4387020131 hasPublicationYear "2023" @default.
• W4387020131 type Work @default.
• W4387020131 citedByCount "0" @default.
• W4387020131 crossrefType "journal-article" @default.
• W4387020131 hasAuthorship W4387020131A5019587154 @default.
• W4387020131 hasAuthorship W4387020131A5020462763 @default.
• W4387020131 hasAuthorship W4387020131A5024982007 @default.
• W4387020131 hasAuthorship W4387020131A5030560916 @default.
• W4387020131 hasAuthorship W4387020131A5059802994 @default.
• W4387020131 hasAuthorship W4387020131A5062757491 @default.
• W4387020131 hasAuthorship W4387020131A5070119477 @default.
• W4387020131 hasAuthorship W4387020131A5072683663 @default.
• W4387020131 hasAuthorship W4387020131A5077282085 @default.
• W4387020131 hasAuthorship W4387020131A5092806576 @default.
• W4387020131 hasAuthorship W4387020131A5092806577 @default.
• W4387020131 hasAuthorship W4387020131A5092806579 @default.
• W4387020131 hasAuthorship W4387020131A5092806580 @default.
• W4387020131 hasBestOaLocation W43870201311 @default.
• W4387020131 hasConcept C113162765 @default.
• W4387020131 hasConcept C116675565 @default.
• W4387020131 hasConcept C126322002 @default.
• W4387020131 hasConcept C159047783 @default.
• W4387020131 hasConcept C187212893 @default.
• W4387020131 hasConcept C2779134260 @default.
• W4387020131 hasConcept C3006700255 @default.
• W4387020131 hasConcept C3007834351 @default.
• W4387020131 hasConcept C3008058167 @default.
• W4387020131 hasConcept C524204448 @default.
• W4387020131 hasConcept C71924100 @default.
• W4387020131 hasConcept C89623803 @default.
• W4387020131 hasConceptScore W4387020131C113162765 @default.
• W4387020131 hasConceptScore W4387020131C116675565 @default.
• W4387020131 hasConceptScore W4387020131C126322002 @default.
• W4387020131 hasConceptScore W4387020131C159047783 @default.
• W4387020131 hasConceptScore W4387020131C187212893 @default.
• W4387020131 hasConceptScore W4387020131C2779134260 @default.
• W4387020131 hasConceptScore W4387020131C3006700255 @default.
• W4387020131 hasConceptScore W4387020131C3007834351 @default.

• next